文献速递淋巴瘤

B细胞特异性IRF4缺失通过增强肿瘤免疫逃逸加速慢性淋巴细胞白血病发展

B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion.
PubMed 文献 · Blood · 2019-01-01

该研究在Tcl-1转基因小鼠中B细胞特异性敲除转录因子IRF4,发现IRF4缺失加速CLL疾病进展,与T细胞活化相关基因严重下调、T细胞亚群偏移和耗竭大幅减少相关;在人类CLL队列中低IRF4表达者预后更差,且T细胞偏移、共刺激能力和活化基因表达均下降。

要点

  • B细胞特异性IRF4缺失加速小鼠CLL进展,与T细胞活化基因下调相关
  • IRF4低表达CLL患者预后更差,T细胞偏移和共刺激能力下降
  • 该免疫逃逸机制独立于T细胞耗竭,或解释免疫治疗失败

核心结论

  • B细胞特异性IRF4缺失通过下调T细胞活化相关基因增强肿瘤免疫逃逸,加速CLL发展,独立于T细胞耗竭。

研究设计与样本

  • 在Tcl-1转基因小鼠中行B细胞特异性IRF4缺失构建小鼠CLL模型。
  • 在独立人类CLL患者队列中验证IRF4表达与预后及T细胞表型的关系。

主要发现

  • IRF4缺陷Tcl-1转基因小鼠CLL疾病进展增强。
  • IRF4缺陷小鼠中T细胞活化相关基因严重下调,包括抗原加工/呈递和T细胞共刺激基因。
  • IRF4缺陷小鼠T细胞亚群偏移和耗竭大幅减少。
  • 人类CLL中IRF4低表达者预后更差,T细胞向抗原经历亚群偏移失败,共刺激能力下降,T细胞活化相关基因下调。

临床怎么用

  • 低IRF4表达可能作为CLL预后不良标志。
  • IRF4相关免疫逃逸机制或解释CLL免疫治疗失败,提示未来靶向改进方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia (CLL) is a heterogenous disease that is highly dependent on a cross talk of CLL cells with the microenvironment, in particular with T cells. T cells derived from CLL patients or murine CLL models are skewed to an antigen-experienced T-cell subset, indicating a certain degree of antitumor recognition, but they are also exhausted, preventing an effective antitumor immune response. Here we describe a novel mechanism of CLL tumor immune evasion that is independent of T-cell exhaustion, using B-cell-specific deletion of the transcription factor IRF4 (interferon regulatory factor 4) in Tcl-1 transgenic mice developing a murine CLL highly similar to the human disease. We show enhanced CLL disease progression in IRF4-deficient Tcl-1 tg mice, associated with a severe downregulation of genes involved in T-cell activation, including genes involved in antigen processing/presentation and T-cell costimulation, which massively reduced T-cell subset skewing and exhaustion. We found a strong analogy in the human disease, with inferior prognosis of CLL patients with low IRF4 expression in independent CLL patient cohorts, failed T-cell skewing to antigen-experienced subsets, decreased costimulation capacity, and downregulation of genes involved in T-cell activation. These results have therapeutic relevance because our findings on molecular mechanisms of immune privilege may be responsible for the failure of immune-therapeutic strategies in CLL and may lead to improved targeting in the future.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Asslaber D, Qi Y, Maeding N, et al. B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion. Blood. 2019. PMID: 31537531. doi:10.1182/blood.2019000973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。